Navigation Links
BIO Ventures for Global Health Announces New CEO

WASHINGTON, Dec. 30 /PRNewswire-USNewswire/ -- BIO Ventures for Global Health announced today that Melinda Moree, PhD, has been named Chief Executive Officer of the global health non-profit. Moree has served as interim CEO of BIO Ventures for Global Health since July 2009 and has been a member of the board of directors since the organization's inception in 2004. Before joining BIO Ventures for Global Health as interim CEO, she served as Executive Director of the Malaria Vaccine Initiative (PATH) and was the Principal Investigator on the Global Health Frontiers project conducted with the Center for Global Development which examined using the commercial drivers of emerging economy markets to increase access to medicines among the poor for chronic and infectious diseases.

"It has been a privilege to work closely with Melinda as a fellow board member and as interim CEO," says Carl B. Feldbaum, Esq., chair of the BIO Ventures for Global Health board. "Her technical expertise, experience in the global health community, and personal diplomacy are just what BIO Ventures for Global Health needs to succeed. Melinda's driving dedication for our mission is inspirational -- we are beyond pleased to have her as CEO."

Until early 2007, Moree was the Director of the Malaria Vaccine Initiative (MVI). MVI is a public-private partnership with a mission to accelerate the development of malaria vaccines and to ensure that they are available and accessible to people in developing countries. While at MVI, Moree was instrumental in setting the overall vision for the program and in ensuring an organizational design and a sense of urgency that enabled rapid execution and solid relations with industry. Under her leadership the first-ever proof of concept that a vaccine could prevent malaria in African children was achieved.

"I love the non-profit sector where we are able to set ambitious goals based solely on the social welfare of the neediest in our society," says Moree. "But it is not non-profits that will make the new drugs, vaccines, and diagnostics to solve the world's greatest unmet medical needs -- it is companies. Finding the common ground between the goals of global health and the pragmatic needs of companies is a complex puzzle that I look forward to solving with our expanding team."

The unique nature of BIO Ventures for Global Health requires depth of knowledge in both global health and the biopharmaceutical industry. BIO Ventures for Global Health will soon make an executive hire from the biopharmaceutical industry that ensures the continuing balance of global health and biopharmaceutical experience at the most senior levels in the organization. "BIO Ventures for Global Health occupies a unique space in the nonprofit world," says Feldbaum. "Through her five-year service on our board, Melinda has become fully aware and equipped to optimally staff BIO Ventures for Global Health."

"Awareness of global health issues is at an historic high. Now BIO Ventures for Global Health must implement its programs quickly and effectively in order to make a real difference to people in poor countries who are suffering from neglected diseases," says Moree. "There is no shortage of goodwill among people in biopharmaceutical companies to work on products for neglected diseases. BIO Ventures for Global Health is committed to finding commercially viable strategies that channel that commitment."

About BIO Ventures for Global Health

BIO Ventures for Global Health is a non-profit organization whose mission is to save lives by accelerating the development of novel biotechnology-based drugs, vaccines, and diagnostics to address the unmet medical needs of the developing world. The organization spurs biotech industry involvement in global health product development by increasing biotech and global health partnerships, designing and advocating for compelling market-based incentives, and synthesizing and disseminating critical information and quantitative analysis. For more information, visit

SOURCE BIO Ventures for Global Health

SOURCE BIO Ventures for Global Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WaferGen Adds Robert Coradini, Former President of J&J New Ventures, to Board of Directors
2. Boston Heart Lab Named Most Promising Early Stage Company 2009 by Silicom Ventures
3. InDex Pharmaceuticals AB Engages PharmaVentures to Facilitate the Licensing of Kappaproct(R) After Phase IIa Trial Achieves Clinical Endpoints Early
4. Apex Bioventures Acquisition Corp. Sets Date for Special Meeting of Stockholders to Approve Dissolution
5. Foundation Radiology Group Raises $10 Million in Venture Funding Led by Chrysalis Ventures
6. JumpStart and Case Technology Ventures Invest in Neuros Medical
7. Hampton Roads Ventures Tackles U.S. Healthcare Crisis Community by Community
8. Apex Bioventures Acquisition Corp. To Seek Stockholder Approval To Liquidate and Dissolve
9. The Commercialization Funding Coach, Fred Patterson, Weighs In On SBIR Funding for Small Business Ventures in Wake of NIH Exclusion
10. Clarus Ventures Hires Former Merck President Ed Scolnick and Broad Institute Scientist Finny Kuruvilla
11. The Adventures of Scooter McDoogal Releases Trilogy of Human Anatomy Comic Books
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: